Tonix Pharmaceuticals Holding Corp TNXP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TNXP is a good fit for your portfolio.
News
-
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
-
Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia
-
Beyond "One Bug, One Drug" - Tonix Pharmaceuticals Secures Up To $34 Million In Funding From The U.S. Department Of Defense To Develop a Broad-Spectrum Antiviral
-
Tonix Pharmaceuticals, Set to File an NDA for Tonmya for the Management of Fibromyalgia, is Planning Expected Launch in 2H 2025
-
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
-
Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering
-
Tonix Pharmaceuticals Announces Proposed Public Offering
-
Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya™ for the Management of Fibromyalgia
Trading Information
- Previous Close Price
- $0.58
- Day Range
- $0.54–0.57
- 52-Week Range
- $0.46–58.24
- Bid/Ask
- $0.55 / $0.56
- Market Cap
- $9.60 Mil
- Volume/Avg
- 1.9 Mil / 1.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.03
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 103
- Website
- https://www.tonixpharma.com
Valuation
Metric
|
TNXP
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.01 |
Price/Sales | 0.03 |
Price/Cash Flow | — |
Price/Earnings
TNXP
Financial Strength
Metric
|
TNXP
|
---|---|
Quick Ratio | 0.34 |
Current Ratio | 1.47 |
Interest Coverage | — |
Quick Ratio
TNXP
Profitability
Metric
|
TNXP
|
---|---|
Return on Assets (Normalized) | −58.87% |
Return on Equity (Normalized) | −70.60% |
Return on Invested Capital (Normalized) | −68.14% |
Return on Assets
TNXP
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Jpvyhvjxg | Bgdw | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Ksrjrst | Kdnjhc | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Wqtzfjvc | Wcwbtd | $118.7 Bil | |||
Moderna Inc
MRNA
| Ybcsjvlc | Dlrbl | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Lnljpjnm | Smdql | $29.7 Bil | |||
argenx SE ADR
ARGX
| Cgvfxnn | Yrkd | $29.3 Bil | |||
BioNTech SE ADR
BNTX
| Dhpbrstj | Fjhl | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Lfhjpdt | Twwlb | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Ytzymfg | Qfgyj | $15.0 Bil | |||
Incyte Corp
INCY
| Zmljcfyn | Gcfrd | $13.5 Bil |